Daratumumab Regimen Keeps 81% of Newly Diagnosed Transplant-Eligible Myeloma Patients Progression-Free at Six Years in PERSEUS Update
In the PERSEUS trial, 81% of myeloma patients on a daratumumab regimen had no progression at six years. What the results mean for patients.
Medical Daily ·